Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $25.87

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as $25.87 and last traded at $26.91, with a volume of 522293 shares traded. The stock had previously closed at $27.73.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Robert W. Baird cut their price target on Arrowhead Pharmaceuticals from $60.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 7th. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, February 10th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $66.00 price target (up previously from $65.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 30th. Morgan Stanley reduced their price objective on shares of Arrowhead Pharmaceuticals from $41.00 to $37.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 10th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $60.10.

Arrowhead Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of $33.79 and a two-hundred day simple moving average of $34.03. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -17.90 and a beta of 1.05.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last issued its quarterly earnings results on Monday, February 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $1.14 by ($1.53). Arrowhead Pharmaceuticals had a negative return on equity of 34.73% and a negative net margin of 54.31%. The business had revenue of $62.55 million for the quarter, compared to analyst estimates of $162.52 million. During the same quarter in the previous year, the business posted ($0.60) earnings per share. The business’s revenue was up 127.9% on a year-over-year basis. Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.4 earnings per share for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 11,350 shares of the stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $32.65, for a total transaction of $370,577.50. Following the completion of the sale, the director now directly owns 7,867 shares in the company, valued at approximately $256,857.55. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Adeoye Y. Olukotun sold 11,350 shares of the firm’s stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $32.65, for a total value of $370,577.50. Following the completion of the sale, the director now directly owns 7,867 shares in the company, valued at approximately $256,857.55. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider James C. Hamilton sold 10,338 shares of the firm’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $38.38, for a total value of $396,772.44. Following the completion of the sale, the insider now owns 145,287 shares of the company’s stock, valued at $5,576,115.06. The disclosure for this sale can be found here. In the last ninety days, insiders sold 102,691 shares of company stock worth $3,864,750. Company insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ARWR. Captrust Financial Advisors raised its holdings in shares of Arrowhead Pharmaceuticals by 22.4% in the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 220 shares during the last quarter. State of Michigan Retirement System raised its stake in shares of Arrowhead Pharmaceuticals by 1.1% in the fourth quarter. State of Michigan Retirement System now owns 26,970 shares of the biotechnology company’s stock worth $1,094,000 after purchasing an additional 300 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 2.7% in the third quarter. Private Advisor Group LLC now owns 11,795 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 313 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 3.5% in the second quarter. O Shaughnessy Asset Management LLC now owns 9,704 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 326 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of Arrowhead Pharmaceuticals by 1.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,180 shares of the biotechnology company’s stock valued at $1,265,000 after buying an additional 329 shares during the last quarter. Institutional investors and hedge funds own 65.46% of the company’s stock.

About Arrowhead Pharmaceuticals

(Get Rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.